Verastem Oncology in the NEWS
On December 30, 2024, Verastem Oncology (VSTM) announced that the U.S. FDA has accepted for review the New Drug Application (NDA) under the accelerated approval pathway for avutometinib. The drug is in combination with defactinib, an oral FAK inhibitor, for the treatment of adult patients with recurrent low-grade serous ovarian cancer (LGSOC . . .
This content is for paid subscribers.
Impacting News
January 6, 2025
 for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer){kind=link}